<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386332</url>
  </required_header>
  <id_info>
    <org_study_id>TPH</org_study_id>
    <nct_id>NCT02386332</nct_id>
  </id_info>
  <brief_title>A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignancies</brief_title>
  <official_title>A Randomized Multicenter Study Comparing Unrelated Umbilical-cord Blood Transplant Versus Human Leukocyte Antigen (HLA)-Haploidentical Related Hematopoietic Stem Cell Transplant for Adult Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigacion Sanitaria La Fe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigacion Sanitaria La Fe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, prospective, observational, multicenter, randomized study to compare&#xD;
      the efficacy between unrelated umbilical cord blood transplantation (UCBT) and&#xD;
      HLA-haploidentical related hematopoietic stem cell transplantation ,after myeloablative&#xD;
      conditioning for adult patients with hematologic malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-Free Survival (DFS)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>umbilical cord blood transplant (UCBT)</arm_group_label>
    <description>Patients to receive umbilical cord blood transplant (UCBT) are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan and anti-thymocyte globulin.). Also receive GVHD prophylaxis with cyclosporine A and prednisone and Additional Supportive Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLA-haploidentical hematopoietic stem cell transplantation</arm_group_label>
    <description>Patients to receive HLA-haploidentical hematopoietic stem cell transplantation are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan). Also receive GVHD prophylaxis with cyclophosphamide, cyclosporine A and mycophenolate mofetil and Additional Supportive Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transplantation</intervention_name>
    <arm_group_label>HLA-haploidentical hematopoietic stem cell transplantation</arm_group_label>
    <arm_group_label>umbilical cord blood transplant (UCBT)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnosed with acute leukemia or myelodysplastic syndrome in which allogeneic&#xD;
        transplantation is considered the most potentially curative therapeutic option&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: subjects ≥ 18 and ≤ 55 years old.&#xD;
&#xD;
          2. Patients without suitable matched related donor&#xD;
&#xD;
          3. Diagnosed with acute leukemia or myelodysplastic syndrome in which allogeneic&#xD;
             transplantation is considered the most potentially curative therapeutic option.&#xD;
&#xD;
          4. Written consent form signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Performance status: Eastern Cooperative Oncology Group(ECOG) score &gt;2&#xD;
&#xD;
          -  Prior allogenic hematopoietic stem cell transplant&#xD;
&#xD;
          -  Left-ventricular ejection fraction at rest &lt; 45%, uncontrolled arrhythmias or&#xD;
             symptomatic heart failure.&#xD;
&#xD;
          -  Diffusing capacity (DLCO) and/or forced vital capacity (FVC) &lt; 39% of predicted values&#xD;
             or symptomatic pulmonary disease&#xD;
&#xD;
          -  Altered liver function tests (total bilirubin &gt; 2 mg/dL and/or alanine&#xD;
             aminotransferase, aspartate aminotransferase , and or active hepatitis or cirrhosis.&#xD;
&#xD;
          -  Serum creatinine &gt; 2 mg/dL or estimated creatinine clearance &lt; 50 mL/min&#xD;
&#xD;
          -  Evidence of uncontrolled bacterial, viral or fungal infection prior to the&#xD;
             conditioning regimen&#xD;
&#xD;
          -  Serious diseases that prevent patients from receiving chemotherapy treatments.&#xD;
&#xD;
          -  Concomitant neoplasms.&#xD;
&#xD;
          -  Pregnancy or breast-feeding.&#xD;
&#xD;
          -  Any other medical, surgical or psychiatric condition that is considered by the&#xD;
             attending and/or medical team as a contraindication for intensive treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel A Sanz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital La Fe, Valencia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miguel A Sanz, MD</last_name>
    <phone>+34.961.245875</phone>
    <email>msanz@uv.es</email>
  </overall_contact>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

